Table 1.

Baseline Characteristics

Demographics and Body Composition
Age (years)	45 (30–59)
Male, no. (%)	41 (44%)
Female, no. (%)	53 (56%)
Height, cm	170 (163–176)
Weight, kg	71 (63–83)
Body mass index, kg/m2	25 (22–28)
Smoking status, no. (%)
Current	3 (3%)
Former	27 (29%)
Never	64 (68%)
Lung function
FEV1, liters	2.9 (2.3–3.4)
FEV1, % predicted	88 (77–101)
FeNO, ppb	20 (12–34)
GINA-stage, no. (%)
1	15 (16%)
2	20 (21%)
3	44 (47%)
4	13 (14%)
5	2 (2%)
Asthma severity, no. (%)
Intermittent	13 (14%)
Mild	42 (45%)
Moderate	35 (37%)
Severe	4 (4%)
Asthma control test at baseline, points	21 (19–23)
Asthma control at baseline, no. (%)
Controlled	66 (70%)
Partially controlled	18 (19%)
Uncontrolled  (Incomplete measurements)	9 (10%) 1 (1%)
Exacerbations within last 12 months, no. (%)
No	34 (36%)
Yes	60 (64%)
Number of exacerbations	2 (1–2)
ED visits due to asthma	11 (13%)
Hospitalizations due to asthma	4 (4%)
Asthma medication, no. (%)	Prescribed	Used
SAMA	5 (5%)	3 (3%)
SABA	52 (55%)	41 (44%)
ICS	86 (91%)	77 (82%)
LABA	78 (83%)	71 (76%)
LAMA	9 (10%)	8 (9%)
Theophylline	0 (0%)	0 (0%)
Systemic corticosteroids	1 (1%)	0 (0%)
LTRA	10 (11%)	10 (11%)
Anti-IgE	0 (0%)	0 (0%)
Anti-IL5	2 (2%)	2 (2%)

Note: Data are expressed as median (interquartile range) unless stated otherwise.

Abbreviations: No., number; FEV1, forced expiratory volume in 1 second; FeNO, fraction of nitric oxide in exhaled air; Ppb, parts per billion; GINA, global initiative for asthma; SAMA, short-acting muscarinic antagonist; SABA, short-acting beta-agonist; ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene-receptor-antagonist; IgE, immunoglobulin E; IL5, interleukin-5; ED, emergency department; ACE, angiotensin-converting enzyme.